Invisalign Gets FDA Warning for Allergy Risk. Low-Dose Naltrexone: Medical Revolution Or Pseudoscience? May 13th, 2010 by Steve Novella, M.D. in Better Health Network, Health Policy, Opinion, Research On SBM we have documented the many and various ways that science is abused in the pursuit of health (or making money from those who are pursuing health). One such method is to take a new, but reasonable, scientific hypothesis and run with it, long past the current state of the evidence. We see this with the many bogus stem cell therapy clinics that are popping up in parts of the world with lax regulation. This type of medical pseudoscience is particularly challenging to deal with, because there is a scientific paper trail that seems to support many of the claims of proponents.
The claims themselves may have significant plausibility, and parts of the claims may in fact be true. Recent claims made for low-dose naltrexone (LDN) fit nicely into this model –- a medical intervention with interesting research, but in a preliminary phase that does not justify clinical use. Background on Naltrexone.
Mental Health. Body maps. Heart health. Genetics. Medical Information & Answers to Medical Questions. Relation between positive small air ions, weather ... [Ann Allergy. 1983] - PubMed result. Migrains headaches research. MEDgle - On-Demand Clinical Case Analysis for Patients and Health Professionals - search your symptoms, diagnoses, drugs, procedures.
Research. Medicines/Remedies. Self Improvement. The Skin Gun.
Food and nutrition. Blocking enzyme cut cancer spread. 22 February 2011Last updated at 05:47 Blocking an enzyme can prevent cells spreading Scientists at the UK's Institute of Cancer Research have prevented breast cancer spreading to other organs in mice by blocking a chemical. In their experiments, they showed that blocking the enzyme LOXL2 prevented metastasis. They said their findings, published in Cancer Research, provided a "fantastic drug target" and were "highly likely" to be used in a clinical setting.
Cancer charities say the research shows great promise. The authors of the report say 90% of cancer deaths are due to tumours migrating around the body. When they looked at patients with breast cancer, they showed that high levels of the enzyme LOXL2 were linked with cancer spread and poor survival rates. They also showed that LOXL2 was important in the early stages of cancer spread. Continue reading the main story “Start Quote This laboratory research shows great promise and we look forward to seeing how it translates into patients” Scientists discover cause of rare skin cancer that heals itself.